SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Ian@SI who wrote (6822)7/30/2002 12:44:19 PM
From: Ian@SI  Read Replies (1) | Respond to of 52153
 
12:17 (Dow Jones) Morgan Stanley says tide is turning for biotechs. Firm has been cautious over past few months, despite what looked like attractive valuations, because of negative sentiment surrounding the group overall and limited news flow during summer months, which is historically the worst performing season for biotech. Morgan Stanley now becoming increasingly positive in outlook. (TG)



To: Ian@SI who wrote (6822)7/30/2002 2:02:22 PM
From: Biomaven  Read Replies (4) | Respond to of 52153
 
Hard to know if Rubin jumped or was pushed. Ultimately he's the one responsible for the Soltara problem, but I was generally impressed with him.

We may be seeing a consequence of the (admirable) decision by the company not to allow its executives to participate in the option repricing.

Peter



To: Ian@SI who wrote (6822)7/30/2002 9:15:48 PM
From: Madharry  Respond to of 52153
 
There cant be too many shoes left to drop. if the guy was incompetent they had better explain why and in a hurry otherwise directors ass can be a sling by people who purchased today.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News